Sabine D. Brookman-May: The right questions addressed by Petros Grivas after NIAGARA trial presentation

Sabine D. Brookman-May shared a post by Roberto Iacovelli, on X, adding:

”The right questions addressed by Petros Grivas after NIAGARA trial presentation:

• Should we proceed with adjuvant treatment in ypT0?
• Is there a role of ctDNA for adjuvant treatment decisions?
• Can patients be cured with systemic therapy bladder sparing approach?”

Quoting Roberto Iacovelli’s post:

”Brilliant discussion by Petros Grivas about NIAGARA trials focused on different roles of neoadjuvant versus adjuvant part of the study and future perspectives opened by this study.”

Source: Sabine D. Brookman-May/X and Roberto Iacovelli/X

Sabine D. Brookman-May is the Vice President of Bladder Cancer Development, Research and Development at Janssen Pharmaceutical Companies of Johnson & Johnson. She also serves as a professor of Urology at Ludwig Maximilian University of Munich, specializing in Urology, Oncology, and Sports and Exercise Medicine.

Roberto Iacovelli, is a medical oncologist at Fondazione Policlinico Gemelli IRCCS in Rome, Italy. With a focus on genitourinary cancers, his research focuses on metastatic renal cell carcinoma, prostate, and bladder cancer, exploring predictive factors and therapy sequencing. Dr. Iacovelli’s contributions include over 150 publications in peer-reviewed journals and numerous awards for his work, including the ASCO Cancer Foundation Merit Award in 2011.